Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey

K. Beyer, RCA. Leenen, LDF. Venderbos, J. Helleman, S. Remmers, V. Vasilyeva, JG. Rivas, E. Briers, T. Frese, J. Vilaseca, S. Vinker, R. Chloupkova, O. Majek, L. Annemans, P. Vynckier, P. Basu, A. Chandran, R. van den Bergh, S. Collen, H. van...

. 2024 ; 14 (7) : . [pub] 20240715

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018232

Grantová podpora
001 World Health Organization - International
101101217 Co-Funded by the European Union

UNLABELLED: In 2022, the European Commission updated its recommendation on cancer screening, inviting the Member States (MSs) to explore the feasibility of stepwise implementation of population-based screening for prostate cancer (PCa). In line with this recommendation, the PRAISE-U (Prostate Cancer Awareness and Initiative for Screening in the European Union (EU)) project was initiated. As part of the PRAISE-U, we aim to understand the current practice towards early detection in the EU MSs, the barriers to implementing or planning population-based screening programmes, and potential solutions to overcome these barriers. METHODS: We adapted the Barriers to Effective Screening Tool (BEST) survey to the PCa context. However, it has not been validated in this context. We translated it into all spoken languages in the EU27 and disseminated it to different stakeholders across the EU using a snowballing approach. RESULTS: We received 410 responses from 55 countries, of which 301 (73%) were from the 27 EU MSs. The most represented stakeholder group was urologists (218 (54%)), followed by general practitioners (GPs) (83 (21%)), patient representatives (35 (9%)), policy stakeholders (27 (7%)), researchers (23 (6%)), oncologists, pathologists, radiologists, nurses, and others (16 (4%)) and one industry representative. Among all respondents, 286 (69%) reported the absence of a population-based screening programme, mainly attributed to resource limitations and a lack of political and medical society support. Out of these 286 respondents, 196 (69%) indicated that opportunistic screening is being applied in their country, and 199 (70%) expressed their support for population-based screening programmes (which was highest amongst patient representatives and urologists and lowest amongst GPs and policy stakeholders). The highest scored barriers were lack of political support, insufficient operational resources, and inadequate participation. Suggested solutions to overcome these included awareness campaigns, consensus meetings, political lobbying and European guidelines (to overcome political support barriers), compatible IT systems (to overcome operational barriers), and easy access (to overcome participation barriers). CONCLUSIONS: Participants have noted the presence of opportunistic screening, and particularly urologists and patient representatives expressed their support for the establishment of a population-based PCa screening programme. Nevertheless, successful implementation of population-based screening programmes is complex; it requires political and medical society support, operational resources and capacity, awareness campaigns, as well as the development of protocols, guidelines, and legal frameworks.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018232
003      
CZ-PrNML
005      
20241016081857.0
007      
ta
008      
241008s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jpm14070751 $2 doi
035    __
$a (PubMed)39064006
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Beyer, Katharina $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands
245    10
$a Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey / $c K. Beyer, RCA. Leenen, LDF. Venderbos, J. Helleman, S. Remmers, V. Vasilyeva, JG. Rivas, E. Briers, T. Frese, J. Vilaseca, S. Vinker, R. Chloupkova, O. Majek, L. Annemans, P. Vynckier, P. Basu, A. Chandran, R. van den Bergh, S. Collen, H. van Poppel, MJ. Roobol, . On Behalf Of The Praise-U Consortium
520    9_
$a UNLABELLED: In 2022, the European Commission updated its recommendation on cancer screening, inviting the Member States (MSs) to explore the feasibility of stepwise implementation of population-based screening for prostate cancer (PCa). In line with this recommendation, the PRAISE-U (Prostate Cancer Awareness and Initiative for Screening in the European Union (EU)) project was initiated. As part of the PRAISE-U, we aim to understand the current practice towards early detection in the EU MSs, the barriers to implementing or planning population-based screening programmes, and potential solutions to overcome these barriers. METHODS: We adapted the Barriers to Effective Screening Tool (BEST) survey to the PCa context. However, it has not been validated in this context. We translated it into all spoken languages in the EU27 and disseminated it to different stakeholders across the EU using a snowballing approach. RESULTS: We received 410 responses from 55 countries, of which 301 (73%) were from the 27 EU MSs. The most represented stakeholder group was urologists (218 (54%)), followed by general practitioners (GPs) (83 (21%)), patient representatives (35 (9%)), policy stakeholders (27 (7%)), researchers (23 (6%)), oncologists, pathologists, radiologists, nurses, and others (16 (4%)) and one industry representative. Among all respondents, 286 (69%) reported the absence of a population-based screening programme, mainly attributed to resource limitations and a lack of political and medical society support. Out of these 286 respondents, 196 (69%) indicated that opportunistic screening is being applied in their country, and 199 (70%) expressed their support for population-based screening programmes (which was highest amongst patient representatives and urologists and lowest amongst GPs and policy stakeholders). The highest scored barriers were lack of political support, insufficient operational resources, and inadequate participation. Suggested solutions to overcome these included awareness campaigns, consensus meetings, political lobbying and European guidelines (to overcome political support barriers), compatible IT systems (to overcome operational barriers), and easy access (to overcome participation barriers). CONCLUSIONS: Participants have noted the presence of opportunistic screening, and particularly urologists and patient representatives expressed their support for the establishment of a population-based PCa screening programme. Nevertheless, successful implementation of population-based screening programmes is complex; it requires political and medical society support, operational resources and capacity, awareness campaigns, as well as the development of protocols, guidelines, and legal frameworks.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Leenen, Renée C A $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands $1 https://orcid.org/000900084561562X
700    1_
$a Venderbos, Lionne D F $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands
700    1_
$a Helleman, Jozien $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands
700    1_
$a Remmers, Sebastiaan $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands $1 https://orcid.org/0000000195306448
700    1_
$a Vasilyeva, Vera $u European Association of Urology, Policy Office, 6842 Arnhem, The Netherlands $1 https://orcid.org/0009000327035625
700    1_
$a Rivas, Juan Gomez $u Department of Urology, Clínico San Carlos University Hospital, 28040 Madrid, Spain $1 https://orcid.org/0000000205563035
700    1_
$a Briers, Erik $u Europa Uomo, 2018 Antwerp, Belgium $1 https://orcid.org/0000000272678449
700    1_
$a Frese, Thomas $u WONCA Europe, Institute for Development of Family Medicine, 1000 Ljubljana, Slovenia
700    1_
$a Vilaseca, Josep $u WONCA Europe, Institute for Development of Family Medicine, 1000 Ljubljana, Slovenia $1 https://orcid.org/0000000215775728
700    1_
$a Vinker, Shlomo $u WONCA Europe, Institute for Development of Family Medicine, 1000 Ljubljana, Slovenia
700    1_
$a Chloupkova, Renata $u National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, 128 01 Prague, Czech Republic $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/000000024091104X
700    1_
$a Majek, Ondrej $u National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, 128 01 Prague, Czech Republic $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000200343084
700    1_
$a Annemans, Lieven $u Department of Public Health and Primary Care, Interuniversity Centre for Health Economics Research, Ghent University, 9000 Gent, Belgium $1 https://orcid.org/0000000183057210
700    1_
$a Vynckier, Pieter $u Department of Public Health and Primary Care, Interuniversity Centre for Health Economics Research, Ghent University, 9000 Gent, Belgium
700    1_
$a Basu, Partha $u International Agency for Research on Cancer, World Health Organization, 90627 69366 Lyon, France
700    1_
$a Chandran, Arunah $u International Agency for Research on Cancer, World Health Organization, 90627 69366 Lyon, France
700    1_
$a van den Bergh, Roderick $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands
700    1_
$a Collen, Sarah $u European Association of Urology, Policy Office, 6842 Arnhem, The Netherlands
700    1_
$a van Poppel, Hendrik $u European Association of Urology, Policy Office, 6842 Arnhem, The Netherlands $u Department of Urology, Gasthuisberg University Hospital, Katholieke Universiteit Leuven, 3000 Leuven, Belgium $1 https://orcid.org/0000000274588578
700    1_
$a Roobol, Monique J $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands $1 https://orcid.org/0000000169671708
700    1_
$a On Behalf Of The Praise-U Consortium,
773    0_
$w MED00203320 $t Journal of personalized medicine $x 2075-4426 $g Roč. 14, č. 7 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39064006 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081853 $b ABA008
999    __
$a ok $b bmc $g 2196501 $s 1230183
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 14 $c 7 $e 20240715 $i 2075-4426 $m Journal of personalized medicine $n J Pers Med $x MED00203320
GRA    __
$a 001 $p World Health Organization $2 International
GRA    __
$a 101101217 $p Co-Funded by the European Union
LZP    __
$a Pubmed-20241008

Najít záznam

Citační ukazatele

Možnosti archivace